Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which patients with prostatic carcinoma require a staging bone scan?

P M Kemp1, G A Maguire, N J Bird

  • 1Department of Nuclear Medicine, Addenbrooke's NHS Trust, Cambridge, UK.

British Journal of Urology
|April 1, 1997
PubMed
Summary

For newly diagnosed prostate cancer patients with prostate-specific antigen (PSA) levels below 20 ng/mL, a staging bone scan is often unnecessary. This finding helps avoid unnecessary procedures for many patients with early-stage prostatic carcinoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaism: a tale of two perspectives.

International journal of clinical practice·2014
Same author

Estimation of lean body mass in children.

British journal of anaesthesia·2011
Same author

Prospective assessment of patient directed outpatient communication from a patient and general practitioner perspective.

Postgraduate medical journal·2009
Same author

A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.

Schizophrenia research·2009
Same author

Reliability of the MDRD method for estimating glomerular filtration rate in relation to gender, body mass index and extracellular fluid volume.

European journal of clinical investigation·2008
Same author

Association between glomerular filtration rate and extracellular fluid volume in normal subjects and patients with renal impairment.

Scandinavian journal of clinical and laboratory investigation·2008

Area of Science:

  • Urology
  • Oncology
  • Radiology

Background:

  • Prostate-specific antigen (PSA) is a biomarker for prostate cancer.
  • Staging bone scans are used to detect metastatic disease in patients with newly diagnosed prostatic carcinoma.

Purpose of the Study:

  • To evaluate the utility of prostate-specific antigen (PSA) levels in determining the need for staging bone scans in newly diagnosed prostate cancer patients.

Main Methods:

  • Retrospective analysis of 98 patients with newly diagnosed prostatic carcinoma who underwent staging bone scans.
  • Serum PSA levels were measured within 4 weeks of bone scans.

Main Results:

  • 26 out of 98 patients with bony metastases detected on bone scan had PSA levels > 40 ng/mL.

Related Experiment Videos

  • Published data indicate that fewer than 1% of newly diagnosed patients with PSA < 20 ng/mL have detectable bony metastases.

    • Conclusions:

    • Staging bone scans can be safely omitted for most patients with newly diagnosed prostatic carcinoma and a PSA level below 20 ng/mL.
    • This approach can reduce unnecessary investigations and healthcare costs.